Member Info for chester18

This is obviously not the reason for there being no news or tweets since the end of April. Checking Twitter just now and still nothing ?

I can only presume that the Radio Silence has something to do with Covidity .

Chester.

Pivotal moment in the journey of Scancell, positive outcomes from this trial will transform the company from potential Baby Bio to a disruptive Biotech force akin to BionTech.

Chester.

Also possible News from one of the following :

AvidiMab Deal
CEPI Interest
Zakari Therapeutics Ltd. reason for being created.

Chester.

Just as a way of reminding us all about Scancells amazing range & depth plus our 'Fourth Platform' and the Interest in it.

**Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said it has generated five drug candidates targeting cancer from its fourth and latest proprietary platform – GlyMab.

The anti-glycan monoclonal antibodies (mAb) created will target specific tumours such as those associated with pancreatic, small cell lung, colorectal and gastric forms of the disease.

In the case of its SC2811 asset, the mAb will interact with a glycolipid identified on T cell stem cells.
Four of the five - SC129, SC27, SC134 and SC88 - have now been successfully humanised, which means they are ready for the next stage of development, Scancell said.
"We believe our proprietary GlyMab platform provides a powerful and versatile approach to generating novel antibody drug candidates that bind to sugar motifs, rather than peptide epitopes, found on the surface of glycosylated proteins and lipids that are implicated as drug targets in particular cancers and potentially other diseases,” added Scancell chief executive, Professor Lindy Durrant.

In the same announcement, investors were told the company has inked an agreement with an unnamed ‘major European pharmaceuticals company’. The new partner, the fourth for the GlyMab platform, wants to ‘further evaluate one of the company's Glymab antibodies for the treatment of cancer’.

Scancell is a clinical-stage life sciences group that owns three other technologies that have generated drug candidates - Moditope and ImmunoBody, its most advanced platforms, are used to develop vaccines and AvidiMab is used to create antibodies.**

That is some kind of Pipeline..
Chester.

The fact that some feel its time to cash out does fly in the face of what's to come.
Two pieces of news will arrive in the short term :
1) The Ovarian Cancer Trial results are probably overdue.
2) The Accreditation of both Pharma Labs, UK and US.

Both of these developments will have an impact on the value of Angle.
If the Ovarian conclusion is that Parsortix strongly benefits patient outcomes its off the the FDA for a much more straightforward approval.

The Pharma Labs when fully licensed and approved will have a huge impact on the companies cash generation. I cannot remember off hand what the projected annual turnover would be but it was suggested that the Labs could be worth todays SP on their own.

IMO, Angle that this moment it time is a Hold / Buy.

Chester.

@ 2cvguy

The article you linked to was interesting and shows that there can be unwanted consequences even with the best of intentions.

The really interesting thing is that ModiTope uses 'Proinflamatory conditions' to work.

Any toxic debris created by ModiTope destroying a tumour that causes Proinflammatory will be swept up by ModiTope, a double whammy.......

Chester.

Hi WTP

I made the decision because we are so close to news landing and that was a good price to maximise how many shares ended up inside my ISA.
Covidity must be working to a decent degree or the trial in SA would not have progressed to the Booster stage.

Just adding 2 plus 2 and in my world I definitely get 4 .

Chester.

Don't worry about the 299,000 sell as reported on Google finance, it was my Bed & ISA of 150k shares less fees.
Sold and bought at 11:17am and virtually at the same price.

Chester.

Hi KonarA

That is a very astute question and something I hadn't thought about.
Not wishing to answer on behalf of Burble but you would think that Scancell will have witnessed that 'void' making in the mouse models. Obviously in a human the void could be considerable dependant on where the solid tumour sits and the type of surrounding tissue.

Under an extreme situation it may be possible to limit the dose level so the tumour regresses over time. Also, the size and placement of a tumour may form part of the current enrolment selection criteria as they would want to initially concentrate on the least complicated cases.

I look forward to Burble giving a more enlightened response.

Chester.

Thanks Bermudashorts

That's good to know and means that June is probably correct for the first dose to be administered. We are so close to finding out if Moditope fulfills the promise so eagerly awaited since 2012. As timelines go we do not have very long to wait.

Chester.

The email message received by bobbust approx 2 weeks ago from LD about ModiFY said from memory, '4 ready to roll, just need a short break from previous treatments before they start'.

What constitutes a short break, 4 to 6 weeks ? and when did the short break start, possibly 4 weeks ago, ish. If the short break does mean short, we can assume that preparations will be being made to administer the First Dose during June.

We could actually receive news on both trials, Covidity and Modify by the end of this month.

That would constitute a Tick Tock news blitz......

Chester.

Let's be real about why the SP has reduced.

Covid, many people jumped on board to make money once Scancell chose to pursue a Covid Vaccine. As we know Covid 'has gone away' so the short term punters have left for speculation pastures anew.

The Stock Market, since the Russian invasion of the Ukraine the markets have been rightly spooked. Any none money making investment has been under downward pressure.

Delays, all three trials SCIB1, Covidity and ModiFY have been delayed due in part to Covid 19 and its impact on clinical services here and in South Africa.

You can say that the current price is at an extreme discount, if, those three trials start to produce positive data.

Chester.

Covidity Trial : All 16 of the original ( Covid Naïve ) subjects will have completed their 26 week trial study period early in June. Fact.
The early data glean from this cohort must have informed the 'Phase1 Trial Changes' announced on the 29th March and confirmed by the updated Clinical Trials website recently.

Will Scancell RNS the findings and the reasons behind the Trial Protocol changes ? I really hope so but the March RNS just says ' update later in 2022'.

Our best hope for early news is if the Data from those first 16 subjects is of material importance to us shareholders, so fingers crossed that the 'T' Cells and the Antibodies produced by Covidity both attacked the Spike Protein and the Nucleocapsid Protein. That would be deemed 'Materially Important' and has to be RNS'ed.

Chester.

No Tweets since the 26th April, a full 6 weeks, no company announcements on any subject and no posters at any conference. This in itself is interesting and is enough of a fact to create speculation.

It doesn't matter which way you look at this fact it does have all the haul marks of an enforced 'Radio Silence' period. Why ?

That's the main cause of our 'what if' posts and that is partly why we enjoy these chat boards.

Chester.

violindog

Regarding what is involved in the ModiFY Trial, if you have not yet read about our trial on : clinical trials.gov here is the link, it is definitely worth reading through.

https://www.clinicaltrials.gov/ct2/show/NCT05329532?term=Scancell&cond=cancer&cntry=GB&draw=2&rank=1

As we have been informed, the 4 enrolled patients that we have will all need to undergo a treatment break period before they can begin their ModiFY journey. As you probably know because of your hospital background Radiotherapy can kill cancer cells a month or more after the last treatment. Scancell need to be absolutely positive that any positive cancer change is down to their drug and not a carry over from previous treatments.

Therefore we must be a little more patient until we hear First Patient Dosed.

But, that announcement is a huge deal both for us and Scancell.

Chester.

The ModiFY Ph.2 trial will be based on a minimum of 300/500 subjects. At that point we will need a large Pharma Co supporting the development and taking a large proportion of the trial / scaling up costs.

At the same time, given that at that point confidence of success will be high, they will be looking for large pre-orders.

As long as progress is maintained and the SA trial proves successful.

Chester.

Hi KonarA

I would think that now Jonathan Van-Tam is employed by Nottingham University he will not only know exactly where we are on the trial but will also be relaying the possibilities of our vaccine to the government health department heads.

There is no doubt that Covidity will be in the view of those in the government that make those kind of decisions.

For me, I agree with you that these new insights into the ongoing and expanded Covidity Trial are excellent to hear.

Chester.

The increase to 80 subjects is the standout amendment.

That change is further evidence that the data from the first 16 subjects met all of the trial goals for the Covid naïve cohort. These protocol shifts are anchored by that initial data.

Chester.

Max

Its quite simple if explained clearly.

The game starts with two men in and they stay in until they are out or the bowling runs out. The side that is in send men out to replace those men that become out by either being bowled out or caught out.

Its the job of the team that's out to ensure that the team that's in are all out.

Can't put it any clearer.

Chester.

As KonarA points out this is ring fencing another potential side shoot from the original ModiTope IP. When ModiFy is proven to work this new offshoot will also be very valuable.

In purely technical speak
'Scancell have more Science than you can poke a stick at'....

Chester.